

Curriculum Vitae

(Updated June. 2022)

Su-Kil Seo, Ph.D.

Department of Microbiology and Immunology

College of Medicine Inje University

Busan 47392, South Korea

Professional Experiences

- 2018.12 - 2020.01 Visiting Researcher, La Jolla Institute for Immunology
2017. 04 - Present Professor, Inje University College of Medicine
2011.04 - 2017. 03 Associate Professor, Inje University College of Medicine
2007.04 - 2011.03 Assistant Professor, Inje University College of Medicine
2005.02 – 2007.03 Full-time Instructor, Inje University College of Medicine

Education and Training

- 2003 - 2004, Postdoctoral Fellow, Immunomodulation Research Center, University of Ulsan
2003, Ph.D. Department of Bioscience, University of Ulsan, Ulsan, Korea (Advisor: BS Kwon)
2000 - 2001 PhD Student research investigator, Louisiana state University Health Science Center, USA
1999, M.S. Department of Bioscience, University of Ulsan, Ulsan, Korea
1997, B.S. Department of Biology, University of Ulsan, Ulsan, Korea

Selected Publications

1. Aryl hydrocarbon receptor-targeted therapy of CD4⁺ T-cell-mediated idiopathic pneumonia syndrome in mice. Lee SM, Kim CE, Park HY, Yoon EH, Won HJ, Ahn JM, Nguyen NZN, Kim M, Jang WH, Lee WS, Kang MS, Jeong M, Yun H, Park S, Wu S, Kim DH, Kwon B and **Seo SK**. Blood. 2022 Jun 2;139(22):3325-3339.
2. IL-33 coordinates innate defense to systemic Candida albicans infection by regulating IL-23 and IL-10 in an opposite way. Nguyen NZN, Tran VG, Baek J, Kim Y, Youn EH, Na SW, Park SJ, **Seo SK**, Kwon B.J Immunol. 2022 Feb 1;208:660-671.
3. Repression of PPAR γ reduces the ABCG2-mediated efflux activity of M2 macrophages Kim CE, Park HY, Won HJ, Kim M, Kwon B, Lee SJ, Kim DH, Shin JG, **Seo SK**. Int J Biochem Cell Biol.2021 Jan;130:105895.

4. Anti-CD137 suppresses tumor growth by blocking reverse signaling by CD137 ligand. Kang SW, Lee SC, Park SH, Kim J, Kim HH, Lee HW, **Seo SK**, Kwon BS, Cho HR, Kwon B. *Cancer Res.* 2017 Nov 1;77(21):5989-6000.
5. Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway. Lee SM, Park HY, Suh YS, Yoon EH, Kim J, Jang WH, Lee WS, Park SG, Choi IW, Choi I, Kang SW, Yun H, Teshima T, Kwon B, **Seo SK**. *Proc Natl Acad Sci U S A.* 2017 Jul 18;114(29):E5881-E5890.
6. Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis. Kang SW, Lee SM, Kim JY, Kim SY, Kim YH, Kim TH, Kang MS, Jang WH, **Seo SK**. *Int Immunopharmacol.* 2017 Jan;42:25-31.
7. Effect of upregulated TLR2 expression from G-CSF-mobilized donor grafts on acute graft-versus-host disease. Lee WS, Kim JY, Won HJ, Lee SM, Suh YS, Joo YD, Lee JY, Jang WH, Kang SW, Kang MS, Park SG, Choi IW, Choi I, **Seo SK**. *Int Immunopharmacol.* 2015 Dec;29(2):488-493.
8. G-CSF-treated donor CD4+ T cells attenuate acute GVHD through a reduction in Th17 cell differentiation. Joo YD, Lee WS, Won HJ, Lee SM, Kim HR, Park JK, Park SG, Choi IW, Choi I, **Seo SK**. *Cytokine.* 2012 Oct;60(1):277-83.
9. G-CSF-induced myeloid cells stimulated by TLR2 enhance engraftment after allogeneic hematopoietic stem cell transplantation. Lee WS, Joo YD, Oh KH, Won HJ, Lee SM, Choi MY, Han GH, Park SG, Choi IW, Choi I, **Seo SK**. *Immunol Lett.* 2012 Apr 30;143(2):177-83.
10. Upregulation of TLR2 expression on G-CSF-mobilized peripheral blood stem cells is responsible for their rapid engraftment after allogeneic hematopoietic stem cell transplantation. Joo YD, Lee WS, Won HJ, Lee SM, Choi JH, Lee SM, Han KH, Park SG, Choi IW, **Seo SK**. *Cytokine.* 2011 Apr;54(1):36-42.
11. Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion. Lee SM, Lee YS, Choi JH, Park SG, Choi IW, Joo YD, Lee WS, Lee JN, Choi I, **Seo SK**. *Immunol Lett.* 2010 Aug 16;132(1-2):53-60
12. Granulocyte colony-stimulating factor-induced immature myeloid cells inhibit acute graft-versus-host disease lethality through an indoleamine dioxygenase-independent mechanism.

Joo YD, Lee SM, Lee SW, Lee WS, Lee SM, Park JK, Choi IW, Park SG, Choi I, **Seo SK**. Immunology. 2009 Sep;128(1 Suppl):e632-40.

13. 4-1BB-mediated immunotherapy of rheumatoid arthritis. **Seo SK**, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, Choi BK, Vinay DS, Kwon BS. Nat Med. 2004 Oct;10(10):1088-94.

14. Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis. **Seo SK**, Park HY, Choi JH, Kim WY, Kim YH, Jung HW, Kwon B, Lee HW, Kwon BS. J Immunol. 2003 Jul 15;171(2):576-83.